{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pemigatinib"]],"indication":"previously treated solid tumors with activating FGFR1-FGFR3 alterations","name":"FIGHT-207","nct_id":"NCT03822117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fight-207-nct03822117. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner\\*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements\\* (not eligible for Cohort A)).\n\n\\*Only FGFR fusions or rearrangements with an intact kinase domain are eligible","label":"Pemigatinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-03-29","type":"ACTUAL"},"conditions":["Solid Tumor Malignancy"],"enrollment":{"count":111,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pemigatinib","otherNames":["INCB054828"],"type":"DRUG"}],"last_update":"2025-11-04","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-03-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements","timeFrame":"up to 483 days"},{"measure":"ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations","timeFrame":"up to 449 days"}],"references":[{"citation":"Rodon J, Damian S, Furqan M, Garcia-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024 Jun;30(6):1645-1654. doi: 10.1038/s41591-024-02934-7. Epub 2024 May 6.","pmid":"38710951","type":"DERIVED"}],"start_date":{"date":"2019-10-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)","url":"https://clinicaltrials.gov/study/NCT03822117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fight-207-nct03822117"}